<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Phathom Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc</link>
<description>Latest news and press releases for Phathom Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/phathom-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ac6278dffbe2df10df87.webp</url>
<title>Phathom Pharmaceuticals Inc</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc</link>
</image>
<item>
<title>Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-april-30-2026</guid>
<pubDate>Mon, 20 Apr 2026 12:00:00 GMT</pubDate>
<description>Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, April 30, 2026, to report its first quarter 2026 financial results and provide a business update. A live webcast and add</description>
</item>
<item>
<title>Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-financial-guidance</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from</description>
</item>
<item>
<title>Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-and-provide-business-update-on-thursday-february-26-2026</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>Management to host conference call on Thursday, February 26, 2026, at 8:00 am ESTFLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. A live w</description>
</item>
<item>
<title>Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-present-guggenheim-emerging-outlook-biotech-summit-2026-2026</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-present-guggenheim-emerging-outlook-biotech-summit-2026-2026</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-pricing-130-033300336</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-pricing-130-033300336</guid>
<pubDate>Thu, 08 Jan 2026 03:33:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock. The shares of common stock are being sold to the public at a price of $16.00 per share and the pre-funde</description>
</item>
<item>
<title>Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-proposed-public-210500102</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-proposed-public-210500102</guid>
<pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering</description>
</item>
<item>
<title>Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-preliminary-fourth-210100059</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-preliminary-fourth-210100059</guid>
<pubDate>Wed, 07 Jan 2026 21:01:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced certain preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025.Preliminary Fourth Quarter 2025 Financial Results For the three months ended December 31, 2025, Phathom expects to report: Net revenues of approximately</description>
</item>
<item>
<title>Shaya Prager Announces Opal Holdings Leasing Activity of 250,000 Square Feet Across Portfolio in 2025</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/shaya-prager-announces-opal-holdings-leasing-activity-of-250000-square-feet-across-portfolio-in-2025</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/shaya-prager-announces-opal-holdings-leasing-activity-of-250000-square-feet-across-portfolio-in-2025</guid>
<pubDate>Tue, 06 Jan 2026 15:37:00 GMT</pubDate>
<description>Opal Holdings LLC ("Opal"), a national commercial real estate owner and operator founded by Shaya Prager, announced today that it has successfully executed approximately 250,000 square feet of leasing activity year-to-date, reflecting increased tenant demand and sustained leasing momentum across its portfolio. Opal's portfolio currently maintains occupancy of over 80%.</description>
</item>
<item>
<title>Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-first-patient-dosed-phase-2-study-voqueznar</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-first-patient-dosed-phase-2-study-voqueznar</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in</description>
</item>
<item>
<title>Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-participate-upcoming-investor-conferences-2025-11-03</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-participate-upcoming-investor-conferences-2025-11-03</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter</description>
</item>
<item>
<title>Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-publication-data-phase-3-phalcon-nerd-301-study</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-publication-data-phase-3-phalcon-nerd-301-study</guid>
<pubDate>Sat, 25 Oct 2025 04:00:00 GMT</pubDate>
<description>Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in</description>
</item>
<item>
<title>Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-highlight-voqueznar-vonoprazan-american-college</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-highlight-voqueznar-vonoprazan-american-college</guid>
<pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-report-third-quarter-2025-financial-results-and-provide</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-report-third-quarter-2025-financial-results-and-provide</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom</description>
</item>
<item>
<title>Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-appoints-sanjeev-narula-chief-financial-and-business-officer</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-appoints-sanjeev-narula-chief-financial-and-business-officer</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational</description>
</item>
<item>
<title>Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-clarifies-there-no-reduction-lead-shareholders-ownership</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-clarifies-there-no-reduction-lead-shareholders-ownership</guid>
<pubDate>Wed, 20 Aug 2025 04:00:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life</description>
</item>
<item>
<title>Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Over 580,000 VOQUEZNA® prescriptions filled to date, reflecting 49% growth since last earnings reportNet revenues of $39.5 million reported for Q2Full-year</description>
</item>
<item>
<title>Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-report-second-quarter-2025-financial-results-and-provide</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-report-second-quarter-2025-financial-results-and-provide</guid>
<pubDate>Mon, 28 Jul 2025 04:00:00 GMT</pubDate>
<description>Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals,</description>
</item>
<item>
<title>Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-1</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-1</guid>
<pubDate>Mon, 23 Jun 2025 04:00:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and</description>
</item>
<item>
<title>Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary</title>
<link>https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-appoints-anne-marie-cook-chief-legal-officer-and-corporate</link>
<guid isPermaLink="true">https://6ix.com/company/phathom-pharmaceuticals-inc/news/phathom-pharmaceuticals-appoints-anne-marie-cook-chief-legal-officer-and-corporate</guid>
<pubDate>Mon, 23 Jun 2025 04:00:00 GMT</pubDate>
<description>FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and</description>
</item>
</channel>
</rss>